CYTARABINE AND CISPLATIN IN ADVANCED MALIGNANT-MELANOMA

  • 1 December 1986
    • journal article
    • research article
    • Vol. 70  (12) , 1441-1442
Abstract
Twenty-seven consecutive patients with advanced malignant melanoma were treated with cytarabine (Ara-C) and cisplatin. Of 25 evaluable patients, four achieved partial response, for a median duration of 3 months. Three of four responders belonged to the group of seven patients given Ara-C at a dose of 3 g/m2. The predominant toxic effect was hematologic and related to the dose of Ara-C. The cost-benefit ratio of this combination is inferior to that of dacarbazine or carmustine alone.